News

NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.

Revisyon is described as a device-led therapy that applies specific wavelengths of low-level LED light to the crystalline lens through a non-invasive, in-clinic procedure.

Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.

AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.

As the 2nd International Glaucoma Symposium approaches in Mainz, Germany, Stephan Schulz highlights how the program bridges everyday clinical needs with the latest advances in AI, imaging, and surgery.

Tenpoint Therapeutics’ YUVEZZI, expected in the US in Q2 2026, is the first fixed-dose combination drop designed to improve near vision via pupil modulation with once-daily dosing.

The trial is evaluating OPGx-MERTK gene therapy for MERTK-related retinitis pigmentosa (RP).

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

A study reveals that low-dose pilocarpine effectively reduces pupil size in presbyopic eyes with minimal impact on lens thickness and accommodation.

This one-day symposium on January 31, 2026, will bring together clinicians and experts at the University Eye Clinic in Mainz to discuss optic neuropathies and diagnostic trends.

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial intelligence applications, and surgical perspectives

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

James Tsai, MD, MBA, sheds light on what is in the offing for glaucoma specialists

James Tsai, MD, MBA, discusses his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can range from highly educated patients to uninformed individuals.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).